Companies · Healthtech
MOUNTAIN VIEW · CA, USA · Healthtech · refined from filed group “Other” · founded 2016 · http://athelas.com
Diligence memoA one-page analyst read on Athelas Inc. — recommendation, valuation, rhythm, risks.→Athelas Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the healthtech sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Athelas Inc. is one of 2138 Healthtech companies tracked from MOUNTAIN VIEW, CA, USA, on record since 2016. By capital raised it ranks among the largest (ahead of 91% of sector peers), and among the largest by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
Extensible, Integrated Technology that Simplifies Health Systems
At Athelas, powered by Commure, our mission is to simplify healthcare. We have bold ambitions to reimagine the healthcare experience, setting a new standard for how care is delivered and experienced across the industry. Our growing suite of AI solutions spans ambient AI clinical documentation, provider copilots, autonomous coding, revenue cycle management and more — all designed for providers & administrators to focus on what matters most: providing care. Healthcare is a $4.5 trillion industry with more than $500 billion spent annually on administrative costs, and Athelas is at the heart of transforming it. We power over 500,000 clinicians across hundreds of care sites nationwide – more than $10 billion flows through our systems and we support over 100 million patient interactions. With new product launches on the horizon, expansion into additional care segments, and a bold vision to tackle healthcare's most pressing challenges, our ambition is to move from upstart innovator to the industry standard over the next few years. Healthcare's moment for AI-powered transformation is here, and we're building the technology to power it. Come join us in shaping the future of healthcare.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 20%.
Round size and date are reported; the stage label is inferred from round size (latest is Series C — a $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the healthtech sector profile. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 2138 companies in Healthtech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 91% of sector peers (real $). Modeled value above 97% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #3 of 39.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Freedom Dental Funding, LLC | Series C | $100.0M | $1.1B | 2.33× |
| Elevate Care International Topco LP | Series C | $98.4M | $1.0B | 2.07× |
| Athelas Inc. this company | Series C | $54.4M | $903.4M | 1.86× |
| Hazel Health, Inc. | Series C | $86.0M | $817.6M | 1.68× |
| Health Gorilla, Inc. | Series C | $58.7M | $816.3M | 1.68× |
| Employee Health Holdings, LP | Series C | $78.8M | $779.7M | 1.60× |
| Magnolia Medical Technologies, Inc. | Series C | $94.2M | $728.3M | 1.50× |
| Allied Health MSO Holdco, LLC | Series C | $62.8M | $724.9M | 1.49× |
| Pearl Health, Inc. | Series C | $55.5M | $721.8M | 1.48× |
| Veridian Healthcare Holdings LLC | Series C | $63.0M | $692.5M | 1.42× |
| Accompany Health, Inc. | Series C | $56.3M | $680.7M | 1.40× |
| Alleviant Medical, Inc. | Series C | $148.8M | $677.4M | 1.39× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Series C | $54.4M | 2022-01-24 | $362.6M | $903.4M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Hemant Taneja | — | 20 other | 2022-01 |
| Deepika Bodapati | — | 1 other | 2022-01 |
| Tanay Tandon | — | 1 other | 2022-01 |
Athelas Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Commure, Inc. | Healthtech | Growth/Late | $1.9B | $56.3M | network3 shared operators · same sector |
| Linus Health, Inc. | Healthtech | Series C | $53.8M | $859.9M | same sector · same stage |
| Sprinter Health, Inc. | Healthtech | Series C | $55.0M | $378.8M | same sector · same stage |
| FCA Health Innovations II QP, LP | Healthtech | Series C | $55.1M | $1.3B | same sector · same stage |
| Pearl Health, Inc. | Healthtech | Series C | $55.5M | $721.8M | same sector · same stage |
| Health Sapiens, LLC | Healthtech | Series C | $52.6M | $1.3B | same sector · same stage |
| Accompany Health, Inc. | Healthtech | Series C | $56.3M | $680.7M | same sector · same stage |
| XO Health Inc. | Healthtech | Series C | $52.2M | $323.7M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Commure, Inc. Commure is reshaping the healthcare landscape with AI-powered solutions that streamline operations, reduce costs, and improve patient and provider experiences. | Healthtech | Growth/Late | $56.3M | 85% |
| AIOS Building AI-native infrastructure for the next era of care. | AI / ML | — | — | 79% |
| Healthcare, Inc. | Healthtech | Series D+ | $4.0B | 76% |
| Asha Health We help medical practices become AI-native | AI / ML | — | — | 76% |
| Attunement Attunement turns fragmented behavioral health records into structured… | Healthtech | — | — | 76% |
| Avelis Health We audit medical claims for self-insured employers and health plans. | Healthtech | — | — | 76% |
| CombineHealth Automating Healthcare Revenue Cycle Management with AI Workforce | HR / Worktech | — | — | 76% |
| Knowtex Making doctors 2x more efficient with AI note-taking & charge capture | Healthtech | — | — | 76% |
See where Athelas Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Athelas Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.